RESUMO
Objective To analyze the clinical treatment effect of edaravone on vascular Parkinson syndrome. Methods 78 patients in our hospital who accepted treatment were selected as the study samples.They were divided into two groups which included treatment group (n =39)and control group (n =39)by random number table meth-od.The control group were given routine treatment,mainly including madopar,aspilin and cripar,however,the treat-ment group administered edaravone on the basis of conventional treatment.After total 2 periods of treatment,the score of UPDR,therapeutic efficacy and adverse reactions were recorded and compared.Results The therapeutic effective rate was 92.31% in the treatment group,which was significantly higer than that of the control group (66.66%),and the difference was statistical significance (χ2 =4.251,P 0.05).The patients in the observation group mental,e -motional and behavioral score were lower than those of the control group (t =4.568,4.113,4.345,all P <0.05),and there was no adverse reaction in the treatment group. Conclusion The treatment of edaravone in vascular Parkinson syndrome can obviously enhance the therapeutic effect,improve the treatment efficiency,has less adverse reaction and good tolerance,it is worth for clinical reference.
